Vlustozik (previously Ibuprofen Gen.Orph) (ibuprofen)
Generic
- Region
- 🇪🇺 EU
- Active substance
- ibuprofen
- Company
- Gen.Orph
- Status
- Authorised
- Therapeutic area
- Ductus Arteriosus, Patent
- EU approval
- Fri 16 Feb 2024
- Designations
- Generic
- Application
- EMEA/H/C/006129
- ATC
- C01EB16
- Official record
- www.ema.europa.eu
Indication
Treatment of a haemodynamically significant patent ductus arteriosus in preterm newborn infants less than 34 weeks of gestational age
Regulatory milestones
No milestones recorded in the last year.
Same substance in other markets
- 🇪🇺 Ibuprofen Gen.Orph Authorised · Gen.Orph
- 🇪🇺 Pedea Authorised · Recordati Rare Diseases
- 🇪🇺 Ibuprofen/Diphenhydramine Hydrochloride Wyeth Application withdrawn · Wyeth Consumer Healthcare
Follow Vlustozik (previously Ibuprofen Gen.Orph)
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.